Dogwood Therapeutics Inc. (VIRI)

Overview

Virios Therapeutics, Inc. is a development-stage biotechnology firm dedicated to creating antiviral therapies aimed at diseases which are believed to have a viral-induced abnormal immune response. Originally operating under the name Virios Therapeutics, LLC, the company underwent a name change in December 2020. Since its inception in 2012, Virios Therapeutics has been committed to exploring innovative solutions to tackle complex viral challenges. Headquartered in Alpharetta, Georgia, the company leverages its expertise in the field to develop treatments that can significantly improve patients' quality of life.

Products and Services

• IMC-1

  IMC-1 represents Virios Therapeutics’ flagship development candidate, combining famciclovir and celecoxib into a fixed dose to address fibromyalgia symptoms. This innovative combination leverages the antiviral properties of famciclovir with the anti-inflammatory benefits of celecoxib, aiming to provide relief to those suffering from this chronic condition that often evades conventional treatment methods.

• IMC-2

  The company is also developing IMC-2, which consists of valacyclovir and celecoxib. This combination targets the management of several post-viral symptoms commonly associated with long COVID, including fatigue, sleep disturbances, attention deficits, pain, problems with autonomic function, and anxiety. The dual-action approach of IMC-2 hopes to address the complex symptomatology of long COVID by not only managing viral replication with valacyclovir but also mitigating inflammation with celecoxib.